Acute ischaemic stroke: reperfusion assessment and early stroke-unit care

Clinical scope and immediate priorities

Acute ischaemic stroke is a time-sensitive neurological emergency in which reperfusion eligibility should be assessed in parallel with stabilisation and diagnosis. The modern pathway is not limited to a rigid clock window; advanced imaging and updated criteria allow selected patients with salvageable brain tissue or favourable anatomy to benefit from treatment later than traditional thresholds. Neurological assessment depends on chronology, focality, level of consciousness and careful exclusion of mimics. Time-sensitive disorders require parallel diagnostic and treatment pathways because waiting for every result can cause avoidable harm. Functional baseline, swallowing, cognition, mobility and medication effects also influence disposition and follow-up.

Recognition and differential diagnosis

Sudden focal weakness, speech or language disturbance, visual loss, neglect, ataxia or altered sensation should trigger a stroke pathway even when symptoms are improving. Posterior circulation stroke may present with diplopia, dysarthria, severe imbalance, vomiting or reduced consciousness and can be missed by face-arm-speech screening tools. Check glucose immediately because hypoglycaemia can mimic stroke. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Establish exact last-known-well time, baseline function, anticoagulant exposure and recent procedures. Non-contrast CT excludes haemorrhage and may show early infarction; CT angiography identifies large-vessel occlusion, while perfusion imaging or MRI can extend treatment selection in appropriate cases. A stroke severity scale supports communication but should not substitute for disability assessment, particularly in posterior circulation or isolated language syndromes. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Eligible patients should receive intravenous thrombolysis without avoidable delay using the locally approved agent and protocol. Endovascular thrombectomy is standard for selected large-vessel occlusions and has expanded to broader anatomical and time-window groups in contemporary guidance. Avoid excessive blood-pressure reduction unless required for reperfusion eligibility or another emergency indication. Admit to a specialist stroke unit and screen swallowing before oral intake. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Large-vessel occlusion, basilar artery occlusion, malignant cerebral oedema, deteriorating consciousness or uncertain reperfusion eligibility requires immediate stroke-specialist and neurointerventional discussion. Decompressive surgery can be life-saving in selected space-occupying infarction. Treat fever, hypoxia and severe glucose disturbance while avoiding routine oxygen in normoxic patients. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Before discharge, establish stroke mechanism and secondary prevention: antiplatelet or anticoagulation strategy, vascular imaging, rhythm assessment, blood pressure, lipids, diabetes management, smoking cessation and rehabilitation needs.

Common pitfalls and safety checks

Do not delay reperfusion treatment for investigations that will not change immediate eligibility. Improving symptoms do not automatically make a patient ineligible if a disabling deficit remains. Posterior circulation stroke can have a deceptively low NIHSS. Swallow screening should precede oral medication, food and drink in patients with potential dysphagia. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Neurological safety depends heavily on transitions of care. Record the patient’s pre-event function, cognition, swallowing, driving or occupational implications and whether family or carers have observed features not seen in clinic. Time-critical imaging and treatment pathways vary in organisation, but delays should be measured and reviewed. Before discharge, make explicit which recurrent symptoms are emergencies, what medicine changes have been made and which team owns follow-up. Rehabilitation needs should be identified alongside disease-specific treatment because mobility, speech and cognition frequently determine outcome.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.